Form 8-K - Current report:
SEC Accession No. 0001842952-25-000024
Filing Date
2025-02-28
Accepted
2025-02-28 16:06:16
Documents
13
Period of Report
2025-02-27
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K cntx-20250227.htm   iXBRL 8-K 22861
  Complete submission text file 0001842952-25-000024.txt   157449

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cntx-20250227.xsd EX-101.SCH 1818
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cntx-20250227_lab.xml EX-101.LAB 24372
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cntx-20250227_pre.xml EX-101.PRE 14143
15 EXTRACTED XBRL INSTANCE DOCUMENT cntx-20250227_htm.xml XML 3001
Mailing Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103
Business Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103 267-225-7416
Context Therapeutics Inc. (Filer) CIK: 0001842952 (see all company filings)

EIN.: 863738787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40654 | Film No.: 25690048
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)